Mangoceuticals, Inc. (MGRX) Stock Price Quote, News &…

Summary

Mangoceuticals, Inc. dedicates its operations to the creation, promotion, and distribution of a variety of health and wellness products and services specifically designed for men. These offerings are primarily delivered through a telemedicine platform. The company's product line includes treatments for erectile dysfunction, marketed under the 'Mango' brand. Consumers can purchase these items directly from its official online portal, mangorx.com. Established in 2021, Mangoceuticals, Inc. is headquartered in Dallas, Texas, and operates as an affiliate of Cohen Enterprises, Inc.

Website

www.mangoceuticals.com

Location

Dallas, TX, US

Phone(214) 242-9619

Employees3

CEOJacob D. Cohen

SectorHealthcare

IndustryMedical - Healthcare Information Services

IPO DateMar 21, 2023

Ask AI

Company overview

Business model, segments, and competition.

Peer comparison

Metrics vs closest competitors.

Guidance & outlook

Forward guidance and assumptions.

Bull vs bear case

Upside drivers and key risks.

Valuation snapshot

Multiples vs history and peers.

Competitive moat

Defensibility and market position.

Management track record

Leadership and capital allocation history.

How it makes money

A short diagram of the business model.

Latest Documents

Mentions in Filings

… ge 62, has been serving as the Chief Financial Officer of 1776 Acquisition Corp, a special purpose acquisition company, since November 2025. Since October 2022, he has been serving as the Chief Financial Officer of Mangoceuticals, Inc. (Nasdaq: MGRX), a men’s health and wellness telemedicine company, where he built the accounting function and led the company through its initial public offering on the Nasdaq Capital Market in March 2023. From Febr …
OFA GroupMangoceuticals, Inc.·8-K - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers·Q2 27·5 Oct
*Mr. Eugene Johnston* has served as our Chief Financial Officer since inception. Mr. Johnston has served as the Chief Financial Officer of Mangoceuticals, Inc. (Nasdaq: MGRX) since October 2022. Since February 2015, Mr. Johnston has served as Audit Manager for Greentree Financial Group, Inc., a financial advisory and consulting firm that provides consulting services to the Company. From August 1999 to September 2014, Mr. Johnston served as Chief …
1776 Acquisition CorpMangoceuticals, Inc.·S-1 - REGISTRATION STATEMENT·Q3 26·3 Aug
***Mr. Eugene Johnston*** has served as our Chief Financial Officer since inception. Mr. Johnston has served as the Chief Financial Officer of Mangoceuticals, Inc. (Nasdaq: MGRX) since October 2022. Since February 2015, Mr. Johnston has served as Audit Manager for Greentree Financial Group, Inc., a financial advisory and consulting firm that provides consulting services to the Company. From August 1999 to September 2014, Mr. Johnston served as Ch …
1776 Acquisition CorpMangoceuticals, Inc.·DRS - Draft registration statement·Q1 26·6 Mar
January 22, 2026 Jacob Cohen Chairman and Chief Executive Officer Mangoceuticals, Inc. 17130 N. Dallas Parkway, Suite 240 Dallas, Texas 75248 Re: Mangoceuticals, Inc. Registration Statement on Form S-1 Filed January 13, 2026 File No. 333-292711 Dear Jacob Cohen: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you t …
Mangoceuticals, Inc.·LETTER - UPLOAD - Filing review upload·27 Jan·27 Jan
January 22, 2026 Jacob Cohen Chairman and Chief Executive Officer Mangoceuticals, Inc. 17130 N. Dallas Parkway, Suite 240 Dallas, Texas 75248 Re: Mangoceuticals, Inc. Registration Statement on Form S-1 Filed January 13, 2026 File No. 333-292711 Dear Jacob Cohen: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind …
Mangoceuticals, Inc.·TEXT-EXTRACT - UPLOAD - Filing review upload·27 Jan·27 Jan

Key Stats

Trading

Px/Chg 1D$0.44 / -9.03%

Avg Volume9.31M

Beta1.77

Mkt Cap7.42M

FD Mkt Cap6.66M

Float

Shrs Out/Float16.97M / 13.43M

Short Float0.08%

Days to Cover1.00

Stock Repurchased$0.00

Current Valuation

EV7.53M

EV/EBITDA-0.43

EV/Sales18.17

P/B0.55

P/S17.89

FCF Yield-17.68%

ROE-25.25%

ROA-23.55%

Current Ratio0.29

Estimates

P/E-0.39

Est P/E0.00

Est EPS0.00

Est PEG0.00

Valuation

Metric	5Yr Avg	May '23	May '24	May '25	May '26	Oct '26
PRICE-BASED RATIOS
Price / Earnings	-2.87	-9.97	-0.38	-0.36	-1.47	-2.18
Price / Sales	477.99	2,227.57	4.83	5.04	43.23	109.28
Price / Book Value	7.61	32.43	4.56	0.22	0.27	0.55
Price / Free Cash Flow	-4.98	-14.33	-0.50	-0.64	-3.78	-5.66
ENTERPRISE VALUE METRICS
Enterprise Value	7.2	19.6	2.9	3.3	2.9	7.5
Enterprise Value / Sales	468.34	2,190.65	4.00	5.30	30.72	111.02
Enterprise Value / EBITDA	-2.86	-9.85	-0.36	-0.41	-1.26	-2.41
Enterprise Value / EBIT	-2.77	-9.83	-0.36	-0.38	-1.05	-2.21

Financials

Full Financials

Millions USD	5Yr CAGR (%)	Dec '21	Dec '22	Dec '23	Dec '24	Dec '25
INCOME STATEMENT
Revenue	—	-	0.0	0.7	0.6	0.5
Gross Income	—	-	0.0	0.4	0.4	0.3
EBITDA	472.5%	-0.0	-2.0	-8.1	-8.0	-18.8
EBIT	485.1%	-0.0	-2.0	-8.1	-8.7	-20.5
Net Income	484.4%	-0.0	-2.0	-9.2	-8.7	-20.6
EPS (Diluted)	228.1%	-0.02	-1.73	-8.58	-4.40	-2.05
BALANCE SHEET
Cash & ST Inv	184.9%	0.0	0.7	0.7	0.1	1.5
Total Assets	416.8%	0.0	1.0	1.1	15.4	16.1
Total Liabilities	118.2%	0.0	0.4	0.3	1.4	0.9
Total Shareholder Equity	—	-0.0	0.6	0.8	13.9	15.2
CASH FLOW
Net Operating Cash Flow	327.5%	-0.0	-1.3	-7.0	-4.9	-5.9
Cap Ex	—	-	-0.0	-0.0	-	-0.0
Free Cash Flow	327.5%	-0.0	-1.4	-7.0	-4.9	-5.9

Enterprise Value Bridge

Millions USD		13 Nov '26
Price (As of 13 Nov '26)		0.16
Basic Shares		16.97
Market Cap		2.6
Diluted Shares		17.12
Fully Diluted Shares Outstanding		17.12
Fully Diluted Market Cap		2.7
+Consolidated Debt		0.3
−In-the-Money Convertible Debt		—
+Capital Leases		0.3
+Operating Leases		—
−Cash & Equivalents		-0.2
−Short-term Investments		-
+Total Preferred		0.0
−In-the-Money Convertible Preferred		—
−Investments in Unconsolidated Subs		—
+Non-Controlling Interest		-0.0
+Pension Liabilities		—
Enterprise Value		2.7

Related companies